Immunomedics Relights its Therapeutic Potential
By Business Review Editor
Pharma Deals Review: Vol 2006 Issue 72 (Table of Contents)
Published: 6 Jun-2006
DOI: 10.3833/pdr.v2006.i72.506 ISSN: 1756-7874
Section: Licensing
Fulltext:
Abstract
UCB Group obtained the worldwide rights to develop, market and sell Immunomedics’ epratuzumab, a humanized monoclonal antibody used for treating autoimmune diseases...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018